{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:39:52Z","timestamp":1780468792268,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science KAKENHI","doi-asserted-by":"crossref","award":["20K07638"],"award-info":[{"award-number":["20K07638"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Doxorubicin is a first-line therapy for patients with unresectable advanced soft tissue sarcoma (STS). However, because of cardiotoxicities, it is not used for patients with cardiac problems. Eribulin has exhibited efficacy for advanced STS in second- or later-line treatments. In the present study, we retrospectively analyzed the efficacy and safety of first-line eribulin therapy for patients with advanced STS unable to receive doxorubicin. Six of 28 patients who received eribulin as any line treatment received eribulin as a first-line treatment. The reasons for avoiding doxorubicin were as follows: cardiac problems for four patients and advanced age for two. Median progression-free survival (PFS) of the patients who received eribulin as first-line and, second or later-line therapy were 9.7\u00a0months (95% CI: 1.0-not reached) and 3.9\u00a0months (95% CI: 2.7\u20135.9), which were not significantly different. The reasons for discontinuation of eribulin were disease progression and adverse events (2 fatigue and 1 neuropathy) for three patients each. No treatment-related cardiotoxicity was observed. The findings of this study indicated that eribulin exhibits meaningful efficacy for the patients with contraindications for doxorubicin as a first-line treatment without cardiac adverse events. However, appropriate safety management is necessary because older patients are typically among those intolerable of doxorubicin.<\/jats:p>","DOI":"10.1038\/s41598-020-77898-y","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T11:05:07Z","timestamp":1606820707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin"],"prefix":"10.1038","volume":"10","author":[{"given":"Kenji","family":"Tsuchihashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyasu","family":"Yoshihiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nokitaka","family":"Setsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Imajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenro","family":"Tanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Arimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyasu","family":"Hanamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taichi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ariyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"77898_CR1","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1002\/cncr.30191","volume":"122","author":"R Ratan","year":"2016","unstructured":"Ratan, R. & Patel, S. R. Chemotherapy for soft tissue sarcoma. Cancer 122, 2952\u20132960 (2016).","journal-title":"Cancer"},{"key":"77898_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","volume":"16","author":"S Raj","year":"2014","unstructured":"Raj, S., Franco, V. I. & Lipshultz, S. E. Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment. Curr. Treat. Options Cardiovasc. Med. 16, 315 (2014).","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"77898_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","volume":"15","author":"I Judson","year":"2014","unstructured":"Judson, I. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol. 15, 415\u2013423 (2014).","journal-title":"Lancet Oncol."},{"key":"77898_CR4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon, B. et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial. Lancet Oncol. 18, 1397\u20131410 (2017).","journal-title":"Lancet Oncol."},{"key":"77898_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.jos.2017.03.017","volume":"22","author":"K Ogura","year":"2017","unstructured":"Ogura, K., Higashi, T. & Kawai, A. Statistics of soft-tissue sarcoma in Japan: Report from the Bone and Soft Tissue Tumor Registry in Japan. J. Orthop. Sci. 22, 755\u2013764 (2017).","journal-title":"J. Orthop. Sci."},{"key":"77898_CR6","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1634\/theoncologist.2017-0598","volume":"23","author":"E Younger","year":"2018","unstructured":"Younger, E. et al. Outcomes of elderly patients with advanced soft tissue sarcoma treated with first-line chemotherapy: A pooled analysis of 12 EORTC soft tissue and bone sarcoma group trials. Oncologist 23, 1250\u20131259 (2018).","journal-title":"Oncologist"},{"key":"77898_CR7","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2013.55.0459","volume":"32","author":"MK Accordino","year":"2014","unstructured":"Accordino, M. K., Neugut, A. I. & Hershman, D. L. Cardiac effects of anticancer therapy in the elderly. J. Clin. Oncol. 32, 2654\u20132661 (2014).","journal-title":"J. Clin. Oncol."},{"key":"77898_CR8","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1093\/annonc\/mdt059","volume":"24","author":"D Garbay","year":"2013","unstructured":"Garbay, D. et al. Advanced soft-tissue sarcoma in elderly patients: Patterns of care and survival. Ann. Oncol. 24, 1924\u20131930 (2013).","journal-title":"Ann. Oncol."},{"key":"77898_CR9","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","volume":"387","author":"P Sch\u00f6ffski","year":"2016","unstructured":"Sch\u00f6ffski, P. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A randomised, open-label, multicentre, phase 3 trial. Lancet 387, 1629\u20131637 (2016).","journal-title":"Lancet"},{"key":"77898_CR10","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA van der Graaf","year":"2012","unstructured":"van der Graaf, W. T. A. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879\u20131886 (2012).","journal-title":"Lancet"},{"key":"77898_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri, G. D. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J. Clin. Oncol. 34, 786 (2016).","journal-title":"J. Clin. Oncol."},{"key":"77898_CR12","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1007\/s12325-017-0561-4","volume":"34","author":"A Kawai","year":"2017","unstructured":"Kawai, A., Yonemori, K., Takahashi, S., Araki, N. & Ueda, T. Systemic therapy for soft tissue sarcoma: Proposals for the optimal use of pazopanib, trabectedin, and eribulin. Adv. Ther. 34, 1556\u20131571 (2017).","journal-title":"Adv. Ther."},{"key":"77898_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jgo.2017.11.003","volume":"9","author":"A de Nonneville","year":"2018","unstructured":"de Nonneville, A. et al. Safety and efficacy of eribulin for \u2018real-world\u2019 older patients with metastatic breast cancer. J. Geriatr. Oncol. 9, 281\u2013283 (2018).","journal-title":"J. Geriatr. Oncol."},{"key":"77898_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/jjco\/hyw175","volume":"47","author":"A Kawai","year":"2017","unstructured":"Kawai, A. et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn. J. Clin. Oncol. 47, 137\u2013144 (2017).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"77898_CR15","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1200\/JCO.2016.71.6605","volume":"35","author":"GD Demetri","year":"2017","unstructured":"Demetri, G. D. et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J. Clin. Oncol. 35, 3433\u20133439 (2017).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77898-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T23:49:42Z","timestamp":1670370582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77898-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77898"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77898-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]},"assertion":[{"value":"8 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.T. received honoraria from Eisai, Chugai Pharma and Novartis Pharma. N.S. received honoraria from Daiichi Sankyo. M.E. received honoraria from Eisai, Taisho, Daiichi Sankyo, Novartis Pharma and Taisho-Toyama. M.E. received consulting fee from Eli Lilly. Y.M. received honoraria from Eisai, Taiho Pharma, Synthes and Medtronic. M.T. received honoraria from Chugai Pharma and Japan Blood Product Organization. H.A. received honoraria from Chugai Pharma. Y.N. received honoraria from Chugai Pharmaceutical, Mitsubishi-Tanabe Pharma, Janssen Pharmaceutical, Pfizer, Eisai, AbbVie, Bristol-Myers Squibb, Astellas, AYUMI, Hisamitsu, Taisho Pharmaceutical, Takeda Pharmaceutical, Zimmer-Biomet and Kyocera. Y.N. received donation from Kyocera. K.A. received honoraria from Astellas Pharm, AbbVie GK, Eisai, Kyowa Kirin, Novartis Pharma, Bristol-Myers Squibb, Celgene, Janssen Pharma, Takeda Pharma, Chugai Pharma, Otsuka Pharma, Daiichi Sankyo, Amgen Astellas BioPharma and Ono Pharma. K.A. received donation from Astellas Pharma, Eisai, Sanofi, Asahi Kasei Pharma, Japan Blood Products Organization, Kyowa Kirin, Mochida Pharma, Ono Pharma, Otsuka Pharma, Shionogi, Yakult Honsh, Sumitomo Dainippon Pharma,Taiho Pharma, Daiichi Sankyo, Chugai Pharma, Nippon Kayaku, Nippon Shinyaku, Nihon Pharma, FUJIFILM Toyama Chemical, Takeda Pharma, Novartis Pharma, MSD and Eli Lilly Japan. E.B. received honoraria from Eli Lilly Japan. No other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20896"}}